Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc operates with a market capitalization of $110.84 million and a price-to-book ratio of 1.17, indicating a relatively modest premium over its book value. The company's liquidity position is strong, with a current ratio of 4.77, suggesting it can comfortably meet its short-term obligations. However, the company has no long-term debt, and its cash and equivalents amount to $19.60 million, which may limit its capacity for large-scale capital expenditures or strategic acquisitions.

Profitability remains a challenge for Inovio, as evidenced by a negative return on equity of -32.26% and a return on assets of -23.60%, both significantly below the industry median for biotechnology firms. The company reported a net loss of $30.47 million for the period, with operating losses of $31.48 million, indicating ongoing operational inefficiencies or high R&D costs. These figures suggest that Inovio is not currently generating returns that meet the expectations of its investors or industry benchmarks.

Geographically and segment-wise, Inovio's revenue concentration is not disclosed in the available data, but the absence of revenue figures implies that the company is in a pre-revenue or early-stage development phase. This lack of revenue diversification could pose a risk if the company's pipeline does not progress to commercialization or if key products fail in clinical trials.

Looking ahead, Inovio's growth trajectory is uncertain. The company has not reported any revenue in the latest financial period, and with a negative operating cash flow of $28.76 million, it is not generating internal cash to fund operations or expansion. Analysts have assigned a mean price target of $6.76, with a median of $6.00, suggesting a potential upside of 380% from the current market price of $1.36. However, the absence of revenue and ongoing losses may limit the company's ability to meet these targets without significant external funding or a major product milestone.

Risk factors for Inovio include its reliance on external financing, as it has no long-term debt and a negative free cash flow of $30.08 million. The risk assessment indicates low dilution potential, but the company's liquidity risk is also rated as low, which may reflect its strong cash position relative to its liabilities. However, the absence of revenue and ongoing losses could change this outlook if the company requires additional capital to fund operations or clinical trials.

Recent events and filings do not indicate any immediate liquidity or dilution risks, but the company's financial position remains precarious given its lack of revenue and ongoing losses. The absence of a clear path to profitability or commercialization of its pipeline products could lead to increased scrutiny from investors and analysts, particularly if the company fails to meet key development milestones.

Inovio Pharmaceuticals Inc (INO.O) has been flagged for its first analysis, establishing a baseline for future monitoring with no prior data available for delta computation. This initial assessment highlights the company's current structural profile, which includes a single reported officer, coverage by six analysts, and membership in zero major indices. The firm currently maintains a top holder count of 16, providing a snapshot of its ownership concentration at this starting point. A notable signal emerged regarding a change in holder activity, specifically an addition to the investor base. This event was detected on June 20, 2026, and pertains to an investor identified by ID 587. The transaction reflects a new position or increase in holdings, marking a distinct shift in the company's shareholder composition relative to the previous state. The specific details of this holder change indicate that as of March 31, 2026, the investor held 300.0 shares. The monetary value of this position was recorded at $0.000522 million, representing a negligible weight of approximately 3.01e-07 percent of the total equity. While the absolute size of the position is minimal, the classification of the event as "notable" suggests it is a tracked data point within the monitoring framework. This initial data set serves as the foundational reference for Inovio Pharmaceuticals, integrating financial, estimate, and ESG data sources [doc:ino.o-ha-financials] [doc:ino.o-ha-estimates] [doc:ino.o-ha-esg]. With no material changes to report against a prior period, the significance of this synthesis lies in establishing the current metrics for officer count, analyst coverage, and holder dynamics. Future updates will measure deviations from this established baseline.

Analysts project 487.9% upside to a mean price target of $6.76, signaling strong market optimism for Inovio Pharmaceuticals.

Operating losses improved by 22.8% year-over-year in FY2026, demonstrating effective cost management and operational efficiency improvements.

The company maintains a zero debt-to-equity ratio, significantly reducing financial leverage risks compared to the biotechnology cohort median.

Cash conversion efficiency stands at 0.94, outperforming the biotechnology cohort median of 0.87, indicating superior cash flow management.

Dilution and liquidity risks are assessed as low, suggesting stable capital structure and adequate short-term financial flexibility.

The company faces high credit risk, indicating significant concerns regarding its ability to meet long-term financial obligations.

Inovio reported a net loss of $84.9 million in FY2026, continuing a persistent pattern of unprofitability over five years.

Revenue $0.00, −100,0% YoY; Operating income +14,2% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +14,2% YoY
• ▍Net income +119,4% YoY
• ▍Free cash flow +121,0% YoY

Revenue $0.00; Operating income +22,4% YoY.

• ▍Revenue $0.00
• ▍Operating income +22,4% YoY
• ▍Net income −80,8% YoY
• ▍Free cash flow −82,7% YoY

Revenue $0.00, −100,0% YoY; Operating income +30,5% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income +30,5% YoY
• ▍Net income +27,0% YoY
• ▍Free cash flow +28,0% YoY

Revenue $65.3k; Operating income +20,4% YoY.

• ▍Revenue $65.3k
• ▍Operating income +20,4% YoY
• ▍Net income +35,4% YoY
• ▍Free cash flow +35,6% YoY
• ▍Net margin -30141.9%

Revenue $117.0k; Operating income -$20.4M.

• ▍Revenue $117.0k
• ▍Operating income -$20.4M
• ▍Net margin -16567.0%

Revenue $0.00; Operating income -$27.3M.

• ▍Revenue $0.00
• ▍Operating income -$27.3M

Revenue $100.8k; Operating income -$33.2M.

• ▍Revenue $100.8k
• ▍Operating income -$33.2M
• ▍Net margin -31993.9%

Revenue $0.00; Operating income -$31.5M.

• ▍Revenue $0.00
• ▍Operating income -$31.5M

Revenue $65.3k, −70,0% YoY; Operating income +22,8% YoY.

• ▍Revenue $65.3k, −70,0% YoY
• ▍Operating income +22,8% YoY
• ▍Net income +20,8% YoY
• ▍Free cash flow +20,9% YoY
• ▍Net margin -130006.0%

Revenue $217.8k, −73,8% YoY; Operating income +21,9% YoY.

• ▍Revenue $217.8k, −73,8% YoY
• ▍Operating income +21,9% YoY
• ▍Net income +20,6% YoY
• ▍Free cash flow +20,1% YoY
• ▍Net margin -49253.4%

Revenue $832.0k, −91,9% YoY; Operating income +46,2% YoY.

• ▍Revenue $832.0k, −91,9% YoY
• ▍Operating income +46,2% YoY
• ▍Net income +51,7% YoY
• ▍Free cash flow +51,6% YoY
• ▍Net margin -16239.9%

Revenue $10.3M, +478,2% YoY; Operating income +11,2% YoY.

• ▍Revenue $10.3M, +478,2% YoY
• ▍Operating income +11,2% YoY
• ▍Net income +7,8% YoY
• ▍Free cash flow +8,8% YoY
• ▍Net margin -2726.7%